Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473420 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT01473420 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 320 participants.
The verdict
NCT01473420, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients treated for anemia associated with chronic renal failure and on hemodialysis.
Interventions
- BIOLOGICAL Epoetin Hospira
- BIOLOGICAL Epogen Amgen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2012-01-17 |
| Est. Completion | 2014-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473420
The ClinicalTrials.gov registry entry for NCT01473420 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Hospira is the first listed.
NCT01473420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473420 about?
NCT01473420 is a clinical study titled "A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin". The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients treated for anemia associated with chronic renal failure and on hemodial...
What is the current status of trial NCT01473420?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2012-01-17. Estimated completion is 2014-02-28.
What interventions are being tested in trial NCT01473420?
The interventions under investigation include: Epoetin Hospira (BIOLOGICAL), Epogen Amgen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01473420?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.